JAMA Paper Says Autonomous AI Could Surpass Physicians and AI-Assisted Care by 2030

The clinical-AI debate is moving beyond whether software can help doctors. A Journal of the American Medical Association paper argues that autonomous AI could deliver better care than both physicians and physician-AI teams by 2030, putting the physician’s role in the care model itself at issue.

The paper, coauthored by Ezekiel Emanuel, Vinod Khosla, Neal Khosla and a researcher associated with Emanuel, answers yes to its own question: whether autonomous AI will exceed physician-AI teams as the best form of medical care.

The case for autonomy

The authors reviewed AI-in-medicine studies published from January 1, 2024 onward. They argue that a superior autonomous system will likely overtake people using AI in five core tasks: taking histories, diagnosing conditions, identifying needed tests, prescribing treatment and managing chronic disease.

The mechanism is not simply better assistance. The paper contends that humans in the loop can degrade AI performance in some medical tasks, making the clinician a potential source of error rather than an essential safeguard.

The real-world challenge

Whyte disputes the paper’s foundation, saying its survey includes simulations rather than blind real-world experiments and that its studies do not uniformly support the conclusion. His position is not that AI lacks promise; it is that the tools should remain inside a physician-governed care plan.

Patient interaction is a concrete constraint on an AI-only model. A February 2026 Nature study cited in the discussion found that most patients in real-life cases could not converse effectively with large language models well enough to access their expertise.

Training is part of the decision

The stakes also reach the training pipeline. The article identifies physician de-skilling as a risk if trainees rely on AI rather than learn history-taking, physical examination and clinical judgment. Whyte says medical schools and residency programs are debating whether trainees should use the tools.

The paper also discloses relevant interests: Vinod Khosla’s investments, Emanuel’s grants and consultancies, and Curai Health’s role. Neal Khosla runs Curai, an online medical company that uses AI alongside doctors who prescribe medication and handle more complicated cases.

Both camps see value in medical AI. The unresolved question is whether the evidence can support autonomous care while patient access to the systems and the effect on clinicians’ training remain contested.